If you run a small medical practice, a dental office, or a specialty clinic, you've been watching tariff news from a distance. Most of it - steel, aluminum, consumer goods - hasn't directly touched your supply cabinet.
That changed on April 2.
President Trump signed a proclamation invoking Section 232 of the Trade Expansion Act, imposing tariffs of up to 100% on imported patented pharmaceuticals and their active ingredients. The tariffs take effect in two waves: July 31, 2026 for some drug manufacturers, and September 29, 2026 for others.
You have a window. Here's how to use it.
What the Tariff Actually Covers
The 100% duty applies to patented pharmaceutical articles - branded drugs listed in the FDA's Orange Book and Purple Book - along with their active pharmaceutical ingredients and key starting materials.
If it's a branded, patent-protected medication, it is in scope.
If it's a generic or biosimilar, it is currently exempt.
That distinction matters enormously for small practices. If your clinic primarily uses generic drugs - as most primary care, family medicine, and general dentistry offices do - your near-term exposure is limited. If you run a specialty practice that regularly stocks or administers branded medications, your cost structure may be changing significantly.
Other exemptions include orphan drugs, plasma-derived therapies, fertility treatments, cell and gene therapies, and certain specialty pharmaceutical categories. The Department of Commerce is expected to clarify the full exemption list.
The Timeline You Need to Know
July 31, 2026 - First wave of companies face the 100% tariff (or 20% if they have an approved domestic production plan).
September 29, 2026 - Second wave takes effect.
April 2, 2030 - The reduced 20% rate (for companies with domestic manufacturing plans) escalates to 100%.
That's not years away. For practices that negotiate drug pricing annually, July is three contract cycles from now.
Why Small Practices Feel This Differently
Large hospital systems have purchasing teams, pharmacy benefits managers, and enough volume to negotiate directly with manufacturers. A small orthopedic practice or independent oncology office does not.
When a large system absorbs a cost increase, they spread it across thousands of patient encounters. When a small practice absorbs it, the options are narrower: raise prices, reduce the formulary of drugs you stock on-site, or pass the cost to patients through additional billing.
The American Hospital Association has flagged that tariff-related cost increases could disproportionately affect smaller providers, particularly in rural and underserved areas where margins are already thin.
What to Do Right Now
Step 1: Audit your drug spend by branded vs. generic. Pull your last 90 days of pharmaceutical procurement. Separate patented branded drugs from generics. That split tells you your actual exposure.
Step 2: Talk to your distributor or GPO before July. Group purchasing organizations (GPOs) and pharmaceutical distributors are already fielding questions about how they will handle tariff pass-through. Some have indicated they will absorb partial increases; others will not. Get clarity in writing before the effective date.
Step 3: Review your reimbursement landscape. If you dispense or administer drugs and bill insurance for them, check how your payers are handling tariff-related cost increases. Some payers are beginning to address this in contract amendments. Others are not - and that silence is worth questioning.
Step 4: Watch the generic exemption status. The Department of Commerce is required to review whether to extend Section 232 tariffs to generics within one year of the proclamation. That means by April 2027, the generic exemption could be revisited. This is not imminent, but it is worth monitoring.
Step 5: If you use specialty drugs regularly, model the cost impact now. A practice that regularly administers an infusion drug at $2,000 per dose, for example, could see that cost approach $4,000 per dose if the tariff applies and the manufacturer passes it through. Model your scenarios at 25%, 50%, and 100% cost increase on your branded drug spend. Know your range before July.
The Bigger Picture
The administration's stated goal is to encourage domestic pharmaceutical manufacturing. The tariff is explicitly designed to make foreign-sourced branded drugs more expensive relative to American-made alternatives.
That goal may have merit at a policy level. For the small medical practice, it does not change the practical reality: procurement costs for certain drugs are going up, the timeline is months away, and preparation now is less painful than scrambling in July.
Generic drugs remain the backbone of most small practice formularies, and they are protected - for now. But practices that have built care models around specific branded medications have real decisions to make before summer.
Dr. Renee Carter covers healthcare small business for The Useful Daily. Sources: White House Presidential Proclamation on Pharmaceutical Tariffs, April 2, 2026, Crowell & Moring Section 232 Pharmaceutical Analysis, JD Supra - From Zero to 100: New Section 232 Tariffs on Pharmaceuticals